객혈 환자의 보존적 치료에서 겉질스테로이드의 효과

The Effect of Corticosteroid in Conservative Treatment of Patients with Hemoptysis

  • 권지숙 (경북대학교 의과대학 내과학교실) ;
  • 유승수 (경북대학교 의과대학 내과학교실) ;
  • 강예림 (경북대학교 의과대학 내과학교실) ;
  • 이정우 (경북대학교 의과대학 내과학교실) ;
  • 김은진 (경북대학교 의과대학 내과학교실) ;
  • 차승익 (경북대학교 의과대학 내과학교실) ;
  • 박재용 (경북대학교 의과대학 내과학교실) ;
  • 정태훈 (경북대학교 의과대학 내과학교실) ;
  • 김창호 (경북대학교 의과대학 내과학교실)
  • Kwon, Jee Suk (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Yoo, Seung Soo (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kang, Yeh Rim (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Lee, Jeong Woo (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kim, Eun Jin (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Cha, Seung Ick (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Park, Jae Yong (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Jung, Tae Hoon (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Kim, Chang Ho (Department of Internal Medicine, School of Medicine, Kyungpook National University)
  • 투고 : 2007.10.25
  • 심사 : 2007.12.12
  • 발행 : 2007.12.30

초록

연구배경: 객혈에 대해 안정, 진해제, 및 항생제 등의 보존적 치료를 요하는 환자에서 단기간의 겉질스테로이드 사용이 미치는 영향을 알아보고자 하였다. 방 법: 2005년 2월부터 2006년 8월까지 객혈을 주소로 응급실을 내원한 환자 중 폐암, 활동성 폐결핵 및 폐렴이 의심되는 환자는 제외하고, 그 중 보존적인 치료를 필요로 하는 환자만을 대상으로 하였다. 이들을 무작위로 겉질스테로이드 투여군(37명)과 대조군(41명)으로 나누어 객혈의 평균 중지 시점, 평균 재원기간 및 합병증에 대하여 전향적으로 조사하였다. 결 과: 비활동성 폐결핵 단독 혹은 그에 합병된 질환을 가진 환자가 가장 많았고(51%), 다음으로 기관지확장증 및 기관지염이 각각 15%였으며, 겉질스테로이드 투여군 과 대조군 사이에 환자의 특성과 원인질환의 분포에 따른 차이는 없었다. 겉질스테로이드 투여군이 대조군에 비해 평균 객혈의 평균 중지 시점($4.0{\pm}2.7$일 vs. $6.1{\pm}4.8$일)과 재원기간($5.8{\pm}3.4$일 vs. $7.9{\pm}4.8$일)이 유의하게 짧았다 (각각 p=0.022, p=0.036). 그리고 겉질스테로이드 사용과 관련된 병원성 폐렴이나 위장관 출혈 등 심각한 합병증의 발생은 없었다. 결 론: 기관지염, 기관지확장증, 비활동성 폐결핵 및 그에 합병된 질환에 의한 객혈의 보존적 치료에서 단기간의 겉질스테로이드 사용은 안전하게 객혈 증상과 재원기간을 단축시킬 수 있는 것으로 사료된다.

Background: This study examined the effect of corticosteroids as a short-term treatment for patients with hemoptysis that requires conservative treatment including bed rest, antitussives and antibiotics. Methods: From February 2005 to August 2006, 78 consecutive patients who visited the emergency room because of hemoptysis were enrolled in the study. Patients with hemoptysis due to lung cancer, active pulmonary tuberculosis, and pneumonia were excluded. The 78 patients were divided randomly into a corticosteroid medication group (n=37) and a control group (n=41). The mean control time of hemoptysis, mean in-hospital days, and complications of treatment were investigated prospectively. Results: For the etiology of hemoptysis, inactive pulmonary tuberculosis alone or its associated complications (bronchiectasis and/or aspergilloma) were the most common causes (51%); bronchiectasis alone and bronchitis were the next most common causative diseases (15%, respectively). The patients' characteristics and symptoms in the corticosteroid medication and control groups were similar. The steroid medication group showed a significantly lower mean control time of hemoptysis than the control group ($4.0{\pm}2.7$ days, $6.1{\pm}4.8$ days, respectively) (p=0.022) and had a lower mean number of in-hospital days ($5.8{\pm}3.4$ days, $7.9{\pm}4.8$ days, respectively) (p=0.036). There were no significant complications, such as hospital-acquired pneumonia or gastrointestinal bleeding, related to the use of corticosteroids. Conclusion: The use of corticosteroids as a conservative treatment for hemoptysis due to bronchitis, bronchiectasis, inactive pulmonary tuberculosis and its related complications safely reduces the control time of hemoptysis as well as the number of in-hospital days.

키워드

참고문헌

  1. Park SK. Hemoptysis. Korean J Med 1988;34:575-82
  2. Bidwell JL, Pachner RW. Hemoptysis: diagnosis and management. Am Fam Physician 2005;72:1253-60
  3. Johnson JL. Manifestations of hemoptysis. How to manage minor, moderate, and massive bleeding. Postgrad Med 2002;112:101-13
  4. Bobrowitz ID, Ramakrishna S, Shim YS. Comparison of medical vs surgical treatment of major hemoptysis. Arch Intern Med 1983;143:1343-6 https://doi.org/10.1001/archinte.143.7.1343
  5. Freixinet J. Surgical indications for treatment of pulmonary tuberculosis. World J Surg 1997;21:475-9 https://doi.org/10.1007/PL00012272
  6. Lee HJ, Um HS, Kim JT, Cho DI, Rhu NS. The clinical study of hemoptysis in lung disease. Tuberc Respir Dis 2000;49:760-73 https://doi.org/10.4046/trd.2000.49.6.760
  7. Pursel SE, Lindskog GE. Hemoptysis. A clinical evaluation of 105 patients examined consecutively on a thoracic surgical service. Am Rev Respir Dis 1961;84:329-36
  8. Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1:152-60 https://doi.org/10.1513/pats.200402-003MS
  9. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7 https://doi.org/10.1056/NEJM199906243402502
  10. Boyer A, Chadda K, Salah A, Annane D. Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality. Int J Clin Pharmacol Ther 2006;44:309-18 https://doi.org/10.5414/CPP44309
  11. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock. Am J Respir Crit Care Med 2003;167:512-20 https://doi.org/10.1164/rccm.200205-446OC
  12. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997;112:440-4 https://doi.org/10.1378/chest.112.2.440
  13. Ozgul MA, Turna A, Yildiz P, Ertan E, Kahraman S, Yilmaz V. Risk factors and recurrence patterns in 203 patients with hemoptysis. Tuberk Toraks 2006;54: 243-8
  14. Hong YP. Tuberculosis in Korea-yesterday, today and tomorrow. Tuberc Respir Dis 1997;44:1-10 https://doi.org/10.4046/trd.1997.44.1.1
  15. Corder R. Hemoptysis. Emerg Med Clin North Am 2003;21:421-35 https://doi.org/10.1016/S0733-8627(03)00009-9
  16. Wang G, Wang YJ, Luo FM, Wang L, Jiang LL, Wang L, et al. Effective use of corticosteroids in treatment of plastic bronchitis with hemoptysis in Chinese adults. Acta Pharmacol Sin 2006;27:1206-12 https://doi.org/10.1111/j.1745-7254.2006.00418.x
  17. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005;353:1711-23 https://doi.org/10.1056/NEJMra050541
  18. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43 https://doi.org/10.1378/chest.111.3.732
  19. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72 https://doi.org/10.1086/511159
  20. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-62 https://doi.org/10.1164/rccm.167.4.603